Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received U.S. Food and Drug Administration (FDA) clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.
Source: itnonline.com